Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Industry, researchers and advocates highlight Connecticut’s rare‑disease ecosystem; coalition warns drug‑affordability boards risk access
Summary
Industry and academic presenters told the Rare Disease Advisory Council that Connecticut’s strong life‑sciences presence and new laboratory methods can advance rare‑disease research, while advocacy groups warned certain state drug‑pricing proposals could harm patient access and innovation.
Industry, researchers and statewide advocates used the council’s public comment period to underscore Connecticut’s strengths in rare‑disease research and to flag emerging policy threats.
Craig Miller, senior director for immunology and respiratory disease research at Boehringer Ingelheim, described the company’s Connecticut presence — including its U.S. headquarters and significant R&D staff — and highlighted collaborations with Yale on systemic sclerosis and other rare conditions. Miller said the company reinvests a substantial portion of revenue into research and maintains numerous external partnerships.
Priyank Patel, a principal scientist at…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
